The promise of ketamine for treatment-resistant depression: Current evidence and future directions

Annals of the New York Academy of Sciences

Volumn 1345, Issue 1, 2015, Pages 47-58

  Dewilde, Kaitlin E ^a   Levitch, Cara F ^a   Murrough, James W ^a   Mathew, Sanjay J ^b   Iosifescu, Dan V ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antidepressant; Bipolar disorder; Ketamine; Major depressive disorder; Treatment resistant

Indexed keywords

ACAMPROSATE; ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CERC 301; CYCLOSERINE; DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS QUINIDINE; ESKETAMINE; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KETAMINE; LAMOTRIGINE; LANICEMINE; LITHIUM; MEMANTINE; MIDAZOLAM; MITOGEN ACTIVATED PROTEIN KINASE; ORG 26575; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; RAPASTINEL; RAS PROTEIN; RILUZOLE; TRAXOPRODIL; UNCLASSIFIED DRUG;

ANHEDONIA; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BIPOLAR DEPRESSION; BLURRED VISION; COGNITION; COGNITIVE DEFECT; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); COORDINATION DISORDER; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MISUSE; EVIDENCE BASED MEDICINE; HAMILTON DEPRESSION RATING SCALE; HUMAN; LEARNING; LOW DRUG DOSE; MAJOR DEPRESSION; MEMORY; MENTAL CONCENTRATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; MOOD DISORDER; NERVE CELL PLASTICITY; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RISK FACTOR; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; WEIRD SENSATION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG EFFECTS; DRUG RESISTANCE; MOOD DISORDERS; PATHOPHYSIOLOGY; PSYCHOLOGY; TREATMENT FAILURE;

ANHEDONIA; ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG RESISTANCE; HUMANS; KETAMINE; MOOD DISORDERS; TREATMENT FAILURE;

EID: 84949089102     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12646     Document Type: Article

References (51)

1. Mathers C., D.M. Fat & J. Boerma . 2008. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization.
2. Undurraga J. & R.J. Baldessarini . 2011. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 37: 851-864.
3. Mathew S.J., A. Shah, K. Lapidus, et al. 2012. Ketamine for treatment-resistant unipolar depression. CNS Drugs 26: 189-204.
4. Fond G., A. Loundou, C. Rabu, et al. 2014. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl.) 231: 3663-3676.
5. McGirr A., M. Berlim, D. Bond, et al. 2014. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol. Med.: 10: 1-12.
6. Murrough J.W., D.V. Iosifescu, L.C. Chang, et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry. 170: 1134-1142.
7. Insel T., B. Cuthbert, M. Garvey, et al. 2010. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167: 748-751.
8. Mathew S.J., J.W. Murrough, K.A. Collins, et al. 2010. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Intl. J. Neuropsychopharmacol. 13: 71-82.
9. Berman R.M., A. Cappiello, A. Anand, et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry. 47: 351-354.
10. Zarate C.A., J.B. Singh, P.J. Carlson, et al. 2006. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63: 856-864.
11. Permoda-Osip A., M. Skibińska, A. Bartkowska, et al. 2014. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr. Pol. 48: 35-46.
12. Diamond P.R., A.D. Farmery, S. Atkinson, et al. 2014. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J. Psychopharmacol. 28: 536-544.
13. Lapidus K.A., C.F. Levitch, A.M. Perez, et al. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry 76: 970-976.
14. Zarate Jr C.A., N. Brutsche, G. Laje, et al. 2012. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol. Psychiatry. 72: 331-338.
15. Diazgranados N., L. Ibrahim, N.E. Brutsche, et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry. 67: 793-802.
16. Murrough J.W., A.M. Perez, S. Pillemer, et al. 2013. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry. 74: 250-256.
17. Pizzagalli D.A. 2014. Depression, stress, and anhedonia: toward a synthesis and integrated model. Ann. Rev. Clin. Psychol. 10: 393-423.
18. Moos R. H. & R. C. Cronkite . 1999. Symptom-based predictors of a 10-year chronic course of treated depression. J. Nerv. Ment. Dis. 187: 360-368.
19. McMakin D.L., T.M. Olino, G. Porta, et al. 2012. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J. Am. Acad. Child Adolesc. Psychiatry 51: 404-411.
20. Spijker J., R. Bijl, R. De Graaf, et al. 2001. Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr. Scand. 103: 122-130.
21. Vrieze E., D.A. Pizzagalli, K. Demyttenaere, et al. 2013. Reduced reward learning predicts outcome in major depressive disorder. Biol. Psychiatry 73: 639-645.
22. Wardenaar K.J., E.J. Giltay, T. van Veen, et al. 2012. Symptom dimensions as predictors of the two-year course of depressive and anxiety disorders. J. Affect. Disord. 136: 1198-1203.
23. Spijker, J., R. de Graaf, M. ten Have, et al. 2010. Predictors of suicidality in depressive spectrum disorders in the general population: results of the Netherlands Mental Health Survey and Incidence Study. Soc. Psychiatry Psychiatr. Epidemiol. 45: 513-521.
24. Lally N., A. Nugent, D. Luckenbaugh, et al. 2014. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl. Psychiatry 4: e469.
25. Murrough J.W., K.E. Burdick, C.F. Levitch, et al. 2014. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology DOI: 10.1038/npp.2014.298.
26. Morgan C.J., L. Muetzelfeldt & H.V. Curran . 2009. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 104: 77-87.
27. Tang W., H. Liang, C. Lau, et al. 2013. Relationship between cognitive impairment and depressive symptoms in current ketamine users. J. Stud. Alcohol Drugs 74: 460.
28. Wan L., C.F. Levitch, A.M. Perez, et al. 2014. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J. Clin. Psychiatry doi: 10.4088/JCP.13m08852.
29. Niciu M.J., I.D. Henter, D.A. Luckenbaugh, et al. 2014. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Rev. Pharmacol. Toxicol. 54: 119-139.
30. Price R.B., M.K. Nock, D.S. Charney, et al. 2009. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry. 66: 522-526.
31. Murrough J.W. & D.S. Charney . 2012. Is there anything really novel on the antidepressant horizon? Curr. Psychiatry Rep. 14: 643-649.
32. Arnone D., A. McIntosh, K. Ebmeier, et al. 2012. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur. Neuropsychopharmacol. 22: 1-16.
33. Li N., R. Liu, J.M. Dwyer, et al. 2011. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69: 754-761.
34. Li N., B. Lee, R.J. Liu, et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
35. Maeng S., C.A. Zarate Jr, J. Du, et al. 2008. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63: 349-352.
36. Autry A.E., M. Adachi, E. Nosyreva, et al. 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91-95.
37. Haile C., J. Murrough, D. Iosifescu, et al. 2014. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Intl. J. Neuropsychopharmacol. 17: 331-336.
38. World Health Organization. 2012. Thirty-Fifth Meeting of the Expert Committee on Drug Dependence. Vol. 35.
39. Li J., B. Vicknasingam, Y. Cheung, et al. 2011. To use or not to use: an update on licit and illicit ketamine use. Substance Abuse Rehabil. 2: 11.
40. Lapidus K.A., L. Soleimani & J.W. Murrough . 2013. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr. Dis. Treat. 9: 1101.
41. Sanacora G., M. Smith, S. Pathak, et al. 2013. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 19: 978-985.
42. Zarate Jr. C.A., D. Mathews, L. Ibrahim, et al. 2013. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol. Psychiatry 74: 257-264.
43. Zarate Jr C.A., J.A. Quiroz, J.B. Singh, et al. 2005. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry 57: 430-432.
44. Duman R.S. & G.K. Aghajanian . 2012. Synaptic dysfunction in depression: potential therapeutic targets. Science 338: 68-72.
45. Beurel E., L. Song & R.S. Jope . 2011. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry 16: 1068-1070.
46. Gould T.D. & H.K. Manji . 2005. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30: 1223-1237.
47. Ghasemi M., M. Raza & A.R. Dehpour . 2010. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J. Psychopharmacol. 24: 585-594.
48. Ibrahim L. et al. 2012. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526-1533.
49. aan het Rot, M. et al. 2010. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67: 139-145.
50. Rasmussen K.G. et al. 2013. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. 27: 444-450.
51. Segmiller F. et al. 2013. Repeated S-ketamine infusions in therapy resistant depression: a case series. J. Clin. Pharmacol. 53: 996-998.